Background: Cancer cachexia adversely affects survival and quality of life but its timely recognition is problematic.
introduction
Weight loss frequently complicates advanced cancer and has been related to increased morbidity, decreased quality of life and poor survival [1] [2] [3] . The term 'cachexia' not only refers to progressive weight loss but also represents a complex metabolic syndrome, which is characterized by inflammation, degradation of skeletal muscle and abnormalities in fat and carbohydrate metabolism [4] . Its prevalence is higher in patients with lung and gastrointestinal tumors [5, 6] .
Recently, it has been recognized that both the persistent cytokine-mediated inflammatory response of the host and the production of catabolic factors by the tumors play a central role for the development of cancer-related cachexia [7] [8] [9] [10] . However, the mechanism of cancer-related cachexia remains incompletely understood [11] . Although a limited number of therapies against cancer-related cachexia have been approved, many drugs will be evaluated in the near future [12] ; nevertheless, to maximize their effectiveness, treatment should be initiated before severe weight loss occurs [13, 14] . The common definition of cancer-associated cachexia, however, is limited to weight loss, reported usually as percentage lost over a defined period of time or compared with usual (premorbid) body weight. Although this has face validity as an approach to screening, it seems insufficient to indicate nutritional risk even when combined with other objective parameters (i.e. tumor stage) [15] . Moreover, there is a gap among the widely used guidelines as to when it is most appropriate to recommend nutritional intervention for weight loss [16] . For these reasons, the use of nutritional screening questionnaires, like the Mini Nutritional Assessment (MNA) [17] , which incorporates both objective and subjective data and may be useful for timely identification of individuals who are at nutritional risk, have been proposed [14, 18] .
Our aim was to evaluate nutritional status of patients with metastatic lung cancer, before the onset of systemic therapy, using the MNA. Patients were also evaluated according to their weight loss history. Results were correlated with laboratory parameters, indicating adverse prognosis, malnutrition and inflammation-cachexia. The predictive and prognostic value of both methods in relation to treatment and disease outcomes were also evaluated. [19] . Patients with a history of a second primary tumor, except nonmelanoma skin tumor, were excluded. Patients with chronic diseases (i.e. chronic renal failure), concurrent infections and/or those who were on any medication that could interfere with the measured laboratory parameters (e.g. nonsteroidal anti-inflammatory drugs) were eligible but they were excluded from the particular laboratory data analysis. All patients provided written informed consent before study entry. The study was approved by the Ethics and Scientific Committees of our Institution.
evaluation Basic demographics [sex, age, weight, height, body mass index (BMI), weight loss history and smoking status], detailed medical history and medications, as well as patients' baseline characteristics [Eastern Cooperative Oncology Group performance status (PS), histological type (non-small-cell lung cancer/small-cell lung cancer), number and location of metastases] were recorded. MNA was completed within 1 week before firstline therapy, to limit any confounding effects of treatment on nutritional status [20] .
The MNA is an 18-item questionnaire validated originally for use in elderly patients with nonmalignant diseases [17] . Questions are divided into two main groups, those of screening and assessment [14] . Screening includes questions related to changes in oral intake, weight loss, mobility, stress and BMI. A score of <11 of 14 on the screening component suggests malnutrition and is the cut point for the full assessment, which additionally includes medical history, specific questions on eating habits and measurements of arm and calf circumferences. A total score is calculated (maximum 30 points). A score of >23.5 points denotes adequate nutritional status (group A), a score of 17.0-23.5 indicates risk of malnutrition (group B) and a score of <17 points categorizes patients as malnourished (group C) [17] . An MNA questionnaire was completed for each patient; in addition, two groups of patients were defined according to their history of weight loss (cut-off 5% during the preceding 3 months), according to standard practice [21] .
Baseline laboratory measurements indicative of adverse prognosis [white blood cell count (WBC), platelets (PLT) (corrected) serum total calcium (Ca), lactate dehydrogenase (LDH)], malnutrition [hemoglobin (Hb), lymphocytes, albumin, creatinine clearance (Cr. clearance)] and inflammation-cachexia [C-reactive protein (CRP), transferrin, ferritin, interleukin (IL)6, tumor necrosis factor-a (TNFa) and IL-8] were also measured.
follow-up
Data from the subsequent first-line systemic treatment such as type of regimen (platinum-based or non-platinum-based combination, singleagent chemotherapy and biologic therapy), worst hematological or nonhematological toxicity according to the National Cancer Institute-Common Toxicity Criteria [22] , requirement and duration (days) of hospitalization, objective response to first-line therapy, time to progression (TTP) and survival data were prospectively collected.
study end points
Our objective was to compare assessment of baseline nutritional status of patients with metastatic lung cancer using a proposed (MNA) and a standard (weight loss history) method. Both methods were further correlated and compared with the laboratory values, indicating adverse outcome, malnutrition, inflammation-cachexia as well as to different parameters characterizing clinical outcome (toxicity and hospitalization requirements during first-line therapy, response, TTP and survival data).
statistical analysis
Data were analyzed using standard statistical methods (chi-square test, Spearman's correlation coefficient, Mann-Whitney test and Kruskal-Wallis test).
For survival analysis, Kaplan-Meier method was used in order to compare the survival curves of each categorical variable, whereas Cox proportional hazards model was used to estimate hazard ratios (HR) with 95% confidence intervals (CI) for univariate or multivariate analysis. Statistical significance was determined by using two-tailed P values and was reported at P < 0.05 level. Statistical analysis was carried out using SPSS (SPSS for Windows, version 15.0, SPSS, Chicago, IL).
results
Nine patients with stage IIIB disease were initially over staged as stage IV and were excluded from the analysis, leaving 173 assessable patients. Two patients died suddenly during initial work-up and for them some data were missing. Eleven (6.3%) patients could not recall their weight loss history, while for 11 (6.3%) patients, height was estimated from the demispan [23] because of frailty.
nutritional assessment
Seventy-three patients (45.0%) had weight loss of >5% during the preceding 3 months; by contrast, assessment by MNA revealed that 48 (27.8%) patients had adequate nutritional status (group A), 80 (46.2%) were at risk for malnutrition (group B) and 45 (26.0%) were already malnourished at presentation (group C). The number of patients requiring some form of nutritional counseling/intervention was significantly higher when assessed by MNA (groups B and C; 72.2%) than that detected by the weight loss history alone (45%; P < 0.001). The proportion of subjects who lost >5% weight in each MNA group is 6.8%, 51.5% and 79.5% for groups A, B and C, respectively.
correlations and clinical outcome
Correlations of weight loss history and MNA with patient demographics and baseline disease characteristics are shown in Table 1 . Both percent weight loss and MNA score correlated with PS (P < 0.001), while MNA also correlated with the number of metastatic sites (P = 0.007) and the presence of brain metastasis (P = 0.022).
The laboratory parameters within weight loss groups and MNA and comparisons between groups are tabulated in Table 2 . MNA was correlated with two of four parameters indicative of adverse outcome, three of four indicative of malnutrition and four of six indicative of inflammation, while weight loss related to two of four, two of four and one of six, respectively.
When the MNA score was considered as a continuous variable, Spearman's test revealed correlations with the cytokines IL-6 and IL-8 (q = 0.209, P = 0.017 and q = 0.298, P = 0.001, respectively). By contrast, TNFa levels exhibited a high original article Annals of Oncology interpatient variability and no significant correlation could be demonstrated.
Neither MNA nor percent of weight loss history was correlated with severe (greater than or equal to grade 3) toxicity to first-line therapy. Nevertheless, only MNA was correlated with a clinical decision taken by the treating physician for less toxic therapy (monochemotherapy/biologic therapy) and with the requirement (P = 0.045) and the duration of hospitalization (P = 0.016).
Percent weight loss as well as MNA score associated with response to first-line therapy (P = 0.012 and P <0.001, respectively). Univariate analysis using the parameters sex, age (20) 3 (7) 26 (29) 15 (20) 1 19 (40) 33 (41) 14 (31) 38 (43) 24 (33) 2 5 (10) 24 (30) 12 (27) <0.001** 17 (19) 19 (26) <0.001** 3 1 (2) 6 (8) 10 (22) 6 (7) 10 (14) 4 0 (0) 1 (1) 6 (13) 2 (2) 5 (7) a In 11 patients weight loss history was unknown. * P < 0.05, ** P < 0.01. MNA, Mini Nutritional Assessment; ns, nonsignificant; NSCLC, non-small-cell lung cancer; PS, performance status; SCLC, small-cell lung cancer; SD, standard deviation. (Table 3) . After a median follow-up of 24.0 months (range 0.07-33.5), univariate analysis using the same parameters revealed that PS, number of metastatic sites, weight loss history, MNA, Hb, albumin and CRP were significantly associated with overall survival (OS). In multivariate analysis, PS (HR = 1.73, 95% CI 1.12-2.68, P = 0.012), MNA (group A versus B: HR = 2.24, 95% CI 1.34-3.75, P = 0.002 and group A versus C: HR = 3.70, 95% CI 1.89-7.27, P < 0.001) and albumin (HR = 0.63, 95% CI 0.44-0.90, P = 0.011) retained their importance (Table 4 ). Survival times were significantly different between weight loss groups and MNA (Figure 1 ). Compared to patients with adequate nutrition according to MNA (group A), those belonging to the intermediate risk (group B) had significantly shorter survival (HR = 2.9, 95% CI 1.9-4.6, P < 0.001), while for malnourished patients (group C), the difference was even more pronounced (HR 7.0, 95% CI 4.1-11.9, P < 0.001). Furthermore, MNA score was associated with median survival in the subgroups of patients stratified according to weight loss history (Spearman's test q = 0.414, P < 0.001 and q = 0.468, P < 0.001 for patients with £5% and >5% weight loss, respectively).
A small number of patients (n = 8) had a 3-month weight loss history of £5% but were malnourished according to the MNA score. These patients had a median survival of 4.4 months, which was consistent with the categorization that they were indeed malnourished. Moreover, five patients had >5% weight loss history but the detailed examination by MNA resulted in their classification as well nourished; their median survival (20.7 months) was also consistent with the MNA classification.
discussion
Weight loss is frequently observed in newly diagnosed metastatic lung cancer patients [7] and considering that these patients will be subsequently subjected to some form of antineoplastic therapy, their nutritional status is expected to diminish further [20] . The presence of weight loss may adversely affect response to treatment and survival [1] [2] [3] and our data confirmed these observations. However, decisions for preventive interventions could not be based solely on this information as when weight loss becomes clinically significant, cachexia may already be irreversible [13, 14] . Furthermore, and aside the fact that the exact percent of weight loss is somewhat subjective and contributes to only one parameter in a multidimensional nutritional evaluation, there is no consensus among oncologists in defining the percent cut-off that should trigger nutritional counseling and/or intervention [16] .
Based on these considerations, it has been proposed that all cancer patients should undergo some form of a baseline nutritional screening [15, 24] . The results of our study strongly support this recommendation; since by comparison with MNA score, weight loss history by itself was a poor discriminator of nutritional status and clinically important outcomes.
Specifically, weight loss history did not correlate or was weakly correlated to 13 of 14 measured laboratory parameters. Moreover, weight loss history was not predictive of the treatment approach chosen in first-line therapy or the duration Although the MNA is a well-established screening and assessment nutritional tool in geriatric patients [25, 26] , experience in patients with malignant diseases is relatively limited. In one trial of patients receiving palliative chemotherapy, MNA score strongly correlated with baseline history of weight loss and the CRP levels [27] . MNA scores were significantly different between patients with prostate cancer and those with benign prostatic hyperplasia [28] . In a recent interventional trial, the MNA was used as an end point of nutritional evaluation after providing instructions and products to enhance flavor of foods and nutritional information, in elderly patients with neoplastic disease [29] .
The results of this observational study emphasize the importance of nutritional screening in newly diagnosed lung cancer patients since the majority of them (>70% according to MNA) will exhibit some degree of nutritional deterioration and support the superiority of MNA versus weight loss history. MNA was better associated with most of the clinical and laboratory data indicating adverse outcome (worse PS, increased number of metastatic sites, presence of brain metastasis, increased Ca and LDH levels), malnutrition (anemia, hypoalbuminemia and low creatinine clearance) and inflammation-cachexia (decreased transferrin levels, increased CRP, IL-6 and IL-8). TNFa was not associated with any of the studied parameters probably due to the short half-time of this cytokine and/or the formation of complexes with the soluble TNF-receptors [30] .
Toxicity during first-line therapy was not different between the various MNA groups but this could be attributed to selection bias, as patients with low MNA score were more likely to receive a less toxic first-line treatment. MNA, but not weight loss history, was significantly associated with both admission to and duration of hospitalization.
Furthermore, MNA was superior to weight loss history in predicting response to first-line treatment.
While both classifications were associated with TTP and OS in univariate analysis, only MNA retained its significance in multivariate analysis. This could be attributed to the incorporated information of weight loss history in the screening component of the MNA. For the same reason, PS did not emerge as an important factor in multivariate analysis for TTP, as MNA also includes mobility-related information equivalent to PS. In multivariate analysis for OS, however, PS still retained its significance.
The two groups of patients above and below 5% weight loss and the three according to MNA had distinct median and 1-year survivals. Indeed, compared with weight loss history, MNA refines further short-term survival estimates, as it defines a subgroup of patients (group C) with poor prognosis and a median survival of only 2.07 months. By contrast, patients classified as adequately nourished (group A) achieved an OS of 17.3 months and a 1-year survival rate of 64.6%. Moreover, MNA stratifies a group of patients (group B) with intermediate risk and a median survival of 6.6 months, in which early anticachectic strategies may be more effective due to the timely demonstration of nutritional deterioration.
It might be possible for patients who relatively maintained their body weight that MNA could better discriminate their nutritional risk due to its input related to inflammationcachexia (like anorexia and the presence of stress), thus predicting the rate by which their weight will eventually decline. On the other hand, patients with significant weight loss could be better stratified by MNA because of the incorporated Annals of Oncology original article information regarding the nutritional reserves, like the baseline BMI and anthropometric measurements. In both cases, MNA score was still significantly associated with median survival. For a minority of patients who were grouped in a completely reversed way (i.e. referred a weight loss history of >5% but had adequate nutrition according to MNA), survival generally followed that predicted by MNA; subjectivity or uncertainty in the self-reported weight loss may contribute to these results.
Another nutritional screening and assessment tool is the Subjective Global Assessment (SGA) [31] , which was validated in cancer patients [32, 33] and has been adapted for that purpose [34] . Read et al. [35] have compared the MNA and Patient-Generated SGA in 157 cancer patients and concluded that while both tools had the same sensitivity in classifying patients as malnourished, MNA lacked specificity. It was emphasized, however, that SGA requires a well-trained person to carry out the assessment and stated that this might be the major limitation of the protocol [35] . Moreover, in elderly cancer patients, similar results with the two protocols were obtained [35] . Others have found that in geriatric patients with nonmalignant diseases assessment with the MNA questionnaire may be a more appropriate nutritional assessment tool than the SGA [36] and that it is better associated with relevant prognostic parameters, like serum albumin and duration of hospitalization [37] .
To better characterize cancer cachexia, more sophisticated methods like height-adjusted indices of fat-free mass, fat mass and skeletal muscle should be used. However, aside from some unresolved methodological issues (undefined reference values, nonstandardized body composition measurements) [11, 38] , these methods could not be generalized and used as a routine test for practical reasons. In addition, a complete nutritional assessment, which incorporates medical history, detailed dietary history, physical examination, anthropometric measurements, laboratory data and, most importantly, would require a registered nutrition professional [15, 39] , could not be routinely applicable.
In oncology practice, an estimation of the baseline nutritional status, by calculating the percent of weight loss, represents a rather oversimplified approach, while, on the other hand, an in-depth nutritional evaluation is clinically impractical in many settings. As new anticachectic strategies are currently tested in preclinical models and early clinical trials [12, 13, [39] [40] [41] , the need for an accurate, practical and nontime-consuming nutritional screening and/or assessment tool on which selection of patients for such treatments could be based upon, is urgent and currently unfulfilled. Specifically, MNA category C patients have a reduced median survival of 2.07 months (95% CI 0.0-4.5 months) as well as an increased chance of hospitalization. This information could be used to exclude or to stratify patients in the context of clinical trials. Moreover, the duration various therapeutic interventions (i.e. hypofractionated radiotherapy, decision to drive patients to a palliative care unit) could be adapted to this limited life expectancy.
MNA meets the aforementioned criteria and should be considered for evaluation of the nutritional status, in lung cancer patients and possibly in patients with other malignancies having the same prevalence of malnutrition. original article
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